Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Assessments

TB Tine A. Bækdal
AB Astrid Breitschaft
MD Morten Donsmark
SM Stine J. Maarbjerg
FS Flemming L. Søndergaard
JB Jeanett Borregaard
ask Ask a question
Favorite

Semaglutide and SNAC were measured by means of validated assays using plasma protein precipitation followed by liquid chromatography with tandem mass spectrometry detection as described previously [20]. The lower limit of quantification (LLOQ) was 0.73 nmol/L for semaglutide and 5.0 ng/mL for SNAC.

Safety assessments included AEs, hypoglycaemic episodes, laboratory safety parameters, physical examination, vital signs and ECG. Hypoglycaemic episodes were defined as ‘confirmed’ when they were either ‘severe’ according to the American Diabetes Association definition, i.e. requiring third party assistance [21], or verified by a plasma glucose level of less than 3.1 mmol/L.

Copyright and License information: The Author(s) ©2021
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A